• By Donald Zuhn –-

    Doggett  LloydA bill introduced in the House last July by Rep. Lloyd Doggett (D-TX) (at right), which could adversely impact pharmaceutical manufacturers holding drug patents, is starting to draw the attention of those outside the patent community.  Last week, National Public Radio reported on the bill (H.R. 6505), entitled the "Medicare Negotiation and Competitive Licensing Act of 2018," which would "require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program."  In particular, the Secretary would negotiate with pharmaceutical manufacturers the prices (including discounts, rebates, and other price concessions) of prescription drugs during a negotiated price period.  In conducting such negotiations, the bill sets out six factors that the Secretary shall take into account when negotiating such drug prices:

    • The comparative clinical effectiveness and cost effectiveness, when available from an impartial source, of such drug.
    • The budgetary impact of providing coverage of such drug.
    • The number of similarly effective drugs or alternative treatment regimens for each approved use of such drug.
    • The associated financial burden on patients that utilize such drug.
    • The associated unmet patient need for such drug.
    • The total revenues from global sales obtained by the manufacturer for such drug.

    One provision of the bill on which pharmaceutical manufacturers have likely focused states that:

    [I]n the case that the Secretary is unable to successfully negotiate an appropriate price for a covered part D drug for a negotiated price period, the Secretary shall authorize the use of any patent, clinical trial data, or other exclusivity granted by the Federal government with respect to such drug as the Secretary determines appropriate for purposes of manufacturing such drug for sale under a prescription drug plan or MA–PD plan.

    The bill requires "[a]ny entity making use of a competitive license to use patent, clinical trial data, or other exclusivity [to] provide to the manufacturer holding such exclusivity reasonable compensation," and sets forth the following factors for use by the Secretary in determining such "reasonable compensation":

    • The risk-adjusted value of any Federal government subsidies and investments in research and development used to support the development of such drug.
    • The risk-adjusted value of any investment made by such manufacturer in the research and development of such drug.
    • The impact of the price, including license compensation payments, on meeting the medical need of all patients.
    • The relationship between the price of such drug, including compensation payments, and the health benefits of such drug.
    • Other relevant factors determined appropriate by the Secretary to provide reasonable compensation.

    The bills, which currently has 104 co-sponsors (all of whom are Democrats), was referred to both the House Energy and Commerce Subcommittee on Health and House Ways and Means Subcommittee on Health.  NPR reported that a related bill would soon be introduced in the Senate by Sen. Sherrod Brown (D-OH).

  • MBHB Logo 2McDonnell Boehnen Hulbert & Berghoff LLP will be offering a live webinar entitled "New Developments in Patent-Eligibility with a Focus on the Abstract Idea Exception" on February 20, 2019 from 10:00 am to 11:15 am (CT).  In this presentation, MBHB attorney and Patent Docs author Michael Borella will provide an up-to-date overview of recent 35 U.S.C. Section 101 happenings, with topics including:

    • An overview of the important Section 101 case law from 2018, including the impact of Berkheimer v. HP
    •
    How to rebut specific types of Section 101 invalidity contentions
    • A discussion of claim drafting to survive Section 101 scrutiny, focusing on machine learning as an example
    • How recent initiatives by Director Andrei Iancu might or might not change how the USPTO views Section 101, including the USPTO's January update to its patent-eligibility examination guidelines

    While there is no fee to participate, attendees must register in advance.  Those wishing to register can do so here.  CLE credit is pending for the states of California, Illinois, New Jersey, New York, North Carolina, and Virginia.

  • LexisNexisLexisNexis will be offering a webinar on "The Next Billion-Dollar Acquisition in Pharma — A Forward-Looking Patent Analysis on Bristol-Myers Squibb Acquiring Celgene" on February 11, 2019 at 2:00 pm (ET).  Gene Quinn of IPWatchdog and Kevin Noonan of Patent Docs will take a look at the recently announced merger between Bristol-Myers Squibb and Celgene, including what the combined company will look like from a patent perspective, and what competition regulators are likely to be interested in questioning about this acquisition.

    Those interested in registering for the webinar, can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Section 112 Issues in IPR Proceedings: Using Section 112 as a Sword or a Shield — Addressing Section 112 Issues in IPR Petitions, Establishing Priority or Earlier Critical Date of Asserted Reference, and More" on February 14, 2019 from 1:00 to 2:30 pm (EST).  Jonathan R. Bowser of Unified Patents and Roger H. Lee of Buchanan Ingersoll & Rooney will provide guidance on Section 112 issues that arise during an inter partes review (IPR) proceeding, address the PTAB's response to assertions that claims do not comply with § 112, discuss related claim construction issues, and offer best practices for handling § 112 issues in IPRs.  The webinar will review the following issues:

    • How has the PTAB responded to assertions made by IPR petitioners that claims do not comply with Section 112?
    • What must patent owners show to establish priority to an earlier application or antedate an asserted reference?
    • What must IPR petitioners show to meet the claim construction requirements for means-plus-function claims under Section 112(f)/sixth paragraph?
    • How does the PTAB weigh prior determinations concerning priority made during prosecution or a patent challenged in an IPR?

    The registration fee for the webcast is $347.  Those interested in registering for the webinar, can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Biotech Patents and Section 101 Rejections: Meeting Patent Eligibility Requirements — Leveraging Recent Decisions and USPTO Guidance to Overcome Rejections" on February 12, 2019 from 1:00 to 2:30 pm (EST).  Amanda K. Murphy, Steven P. O'Connor, Sanya Sukduang, and Sara A. Leiman of Finnegan Henderson Farabow Garrett & Dunner will guide patent counsel for overcoming § 101 rejections for biotech patents, review recent case law and USPTO guidance on § 101 patent eligibility, and offer strategies to address § 101 rejections.  The webinar will review the following issues:

    • The impact of the Mayo, Myriad, and Ariosa decisions on recent USPTO and Federal Circuit decisions addressing § 101 rejections for biotech and other technological patents
    • Problems with the USPTO guidance documents and examiner training
    • Potential strategies to overcome § 101 rejection
    • Robust patent specification and claim drafting tips

    The registration fee for the webcast is $347.  Those interested in registering for the webinar, can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Conducting and Analyzing Prior Art Searches — Strategies for Validity, Patentability, Infringement, FTO and State-of-the-Art Searches" on February 27, 2019 from 1:00 to 2:30 pm (EST).  Thomas L. Irving and Christopher C. Johns of Finnegan Henderson Farabow Garrett & Dunner, Kim Jordahl of KSJLaw, and Stephanie Curcio of Legalicity will guide patent counsel on structuring and conducting prior art searches, discuss reporting of search results and offer best practices for analyzing prior art searches to maximize patent protection.  The webinar will review the following issues:

    • What are the critical considerations when determining what, when and where to search?
    • What are the critical components of an effective search strategy, analytical process and follow-up steps to ensure a successful patent application?

    The registration fee for the webcast is $347.  Those interested in registering for the webinar, can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Infringement of IP Rights in Augmented and Virtual Reality — Protecting and Monitoring Trademarks, Right of Publicity, Copyrights" on February 21, 2019 from 1:00 to 2:30 pm (EST).  J Alexia Bedat of Klaris Law, Kimberly Culp of Carr McClellan, and James G. Gatto of Sheppard Mullin Richter & Hampton will guide counsel on intellectual property infringement issues that arise in augmented reality (AR) and virtual reality (VR); discuss steps that IP owners can take to monitor and police use of their marks, copyrights, and images; and discuss what game developers, creators, and owners can do to mitigate the risk of infringing on real-world IP rights.  The webinar will review the following issues:

    • What monitoring programs should real-world IP owners and counsel put in place to protect IP rights from being infringed in AR and VR?
    • What other steps can IP owners take to prevent infringement of their IP rights in AR and VR?
    • What are the hurdles to protecting IP in augmented and virtual worlds?

    The registration fee for the webcast is $347.  Those interested in registering for the webinar, can do so here.

  • By Kevin E. Noonan —

    Federal Circuit SealThe Federal Circuit has on several occasions taken the opportunity to address (and in doing so, flesh out) the requirements for Article III standing to appeal an adverse determination in a post-grant review proceeding (post-grant review, inter partes review, and covered business method patent review) against a Petitioner (loss of patent claims typically provides sufficient injury for a Patent Owner to have standing).  See, for example, Consumer Watchdog v. Wisconsin Alumni Research Foundation; Phigenix, Inc. v. ImmunoGen, Inc.; E. I. du Pont de Nemours & Co. v. Synvina C.V.; and most recently, Amerigen Pharmaceuticals Ltd. v. UCB Pharma GmbH.  But the Court has not had a clearer factual basis for deciding that a failed Petitioner did not have standing under Article III than in Momenta Pharmaceuticals v. Bristol-Myers Squibb, decided today.

    The case involved a inter partes review (IPR) brought by Momenta against all claims of U.S. Patent No. 8,476,239 having claims reciting "specific fluid formulations of the protein molecule CTLA4Ig (cytotoxic T-lymphocyte associated protein 4 immunoglobulin)."  These formulations were used to treat, inter alia, rheumatoid arthritis, having the generic name abatacept and sold by BMS as Orencia®.  The PTAB instituted but sustained the patentability of all claims.  This appeal followed.

    However, certain additional facts outside the basis for the PTAB's decision were relevant to the decision reached by the panel.  While not needing to establish standing to petition for IPR, Momenta at that time was pursuing research for the development of a biosimilar version of Orencia®.  However, during the course of the IPR trial, Momenta's biosimilar candidate failed clinical testing and was withdrawn by Momenta from FDA review.  BMS moved to dismiss the appeal on the grounds that these actions deprived Momenta of standing, insofar as there was no prospect of injury if Momenta was not pursuing its biosimilar.  The Court heard argument on the motion as well as the merits and retired to confer.

    While conferring, Momenta brought two other facts to the Court's attention.  First, on October 18, 2018 (after oral argument), Momenta filed a Letter to the Court (permitted under Fed. R. App. P. 28(j)) along with a press release, informing the Court that Momenta had "has initiated discussions with its collaboration partner, Mylan, to exit its participation in the development of its other five biosimilar programs including M834, a proposed biosimilar to ORENCIA® . . . ."  This prompted the Court to issue an Order to Show Cause (on October 23rd) why the Court should not dismiss the appeal.  Ten days later Momenta responded that:

    As of today, the companies continue to be jointly responsible under that agreement for product development and for sharing the costs of that development, which are substantial.  And because of BMS's patent and the Board's decision upholding it, Momenta and its partner Mylan still face the same fork in the road about the commercial formulation for their biosimilar product—they must decide whether to proceed with the current formulation or switch to a more expensive and potentially less commercially viable option.  That decision and the costs associated with it still turn on the outcome of this appeal.

    Momenta's response was supported by a declaration from its Chief Business Officer that the parties had not reached a decision whether to terminate the Orencia® biosimilar development program.  In addition, Momenta asserted its "economic interest" in any Orencia® biosimilar that might be developed by Mylan, which included "potential right to royalties."  A little more than a month later, on December 10th, Momenta filed another letter with the Court, informing the panel of a Preliminary Prospectus Supplement and Form 8-K filed with the Securities and Exchange Commission four days before, which notified the SEC and prospective investors that:

    We have elected to terminate our collaboration agreement with Mylan with respect to the development of . . . M834, a proposed biosimilar to ORENCIA® . . . .  On November 19, 2018, we delivered a formal notice of this partial termination to Mylan, as provided in the collaboration agreement.

    Momenta made no response to BMS's further argument that the appeal was mooted by these developments, nor did the company withdraw its appeal.

    Judge Newman rendered the Court's decision, joined by Judges Dyk and Chen.  Calling the "constitutional limitation of federal-court jurisdiction to actual cases or controversies" the most fundamental principle defining the judiciary's proper role, citing Raines v. Byrd, 521 U.S. 811, 818 (1997), the opinion addressed Momenta's argument that the requirement for standing for judicial review of agency decisions was "relaxed" relative to district court litigation.  These requirements are that an appellant must have "(1) suffered an injury in fact, (2) that is fairly traceable to the challenged conduct of the defendant, and (3) that is likely to be redressed by a favorable judicial decision."  Spokeo, Inc. v. Robins, 136 S. Ct. 1540, 1547 (2016)).  The panel recognized that some relaxation has been recognized, for example in Lujan v. Defenders of Wildlife, 504 U.S. 555 (1992) and Massachusetts v. E.P.A., 549 U.S. 497, 517–18 (2007).  Indeed, the Supreme Court has held that "[p]arties that initiate the [Inter Partes Review] proceeding need not have a concrete stake in the outcome; indeed, they may lack constitutional standing" in Cuozzo Speed Technologies, LLC v. Lee, 136 S. Ct. 2131, 2143–44 (2016).

    But that relaxation does not extend to the requirement of "injury in fact," which is a hard floor of Article III jurisdiction that cannot be removed by statute, citing Summers v. Earth Island Institute, 555 U.S. 488 (2009).  The basis for this "hard floor, according to the opinion, is that without it courts would be reduced to writing advisory opinions.  Congress does not have the power to do so by statute, as recognized in Consumer Watchdog v. Wis. Alumni Research Found. and Gladstone, Realtors v. Village of Bellwood, 441 U.S. 91, 100 (1979).  Under the facts as they had developed, Momenta was unable to show "'an invasion of a legally protected interest' that is 'actual or imminent, not conjectural or hypothetical'" as required under the Supreme Court's Lujan decision.

    Momenta's alternative argument, that the estoppel provisions of IPR proceedings under 35 U.S.C. § 315(e), were similarly unavailing in the face of evidence that Momenta was not longer engaging in activity that could lead to infringement liability.  The argument that Momenta might be injured "at some future time" if Mylan developed an Orencia® biosimilar from the sale of which Momenta would be entitled to royalties was too attenuated to provide injury-in-fact, the opinion citing Clapper v. Amnesty Int'l USA, 568 U.S. 398, 414 n.5 (2013), that a plaintiff "cannot rely on speculation about the unfettered choices made by independent actors" not before the court.  Momenta's position was contrary to several Federal Circuit decisions on standing for appealing PTAB decisions, including Consumer Watchdog, Phigenix, Inc. v. Immunogen, Inc., and RPX Corp. v. ChanBond LLC, No. 17–2346, ECF 39 (Fed. Cir. Jan. 17, 2018).  In cases where lacking a product on the market was not enough to preclude Article III standing, the petitioner had "concrete plans for future activity that creates a substantial risk of future infringement," JTEKT Corp. v. GKN Automotive Ltd., 898 F.3d 1217, 1220–21 (Fed. Cir. 2018), or the parties were "direct competitors and were in commercial dispute" and the petitioners faced "a significant risk of patent infringement in their demonstration plant that was entering into operation," E.I. DuPont de Nemours & Co. v. Synvina C.V., 904 F.3d 996, 1005 (Fed. Cir. 2018).  None of these facts were present here.

    And while recognizing that "[s]tanding and mootness may not be coextensive in all cases," none of the exceptions ("when the issue has avoided review and is likely to be repeated, or when the defendant voluntarily ceased the challenged activity and the plaintiff seeks to preserve its win") applied here.  Accordingly, the Court dismissed the appeal as moot.

    Momenta Pharmaceuticals, Inc. v, Bristol-Myers Squibb Co. (Fed. Cir. 2019)
    Panel: Circuit Judges Newman, Dyk, and Chen
    Opinion by Circuit Judge Newman

  • By Donald Zuhn –-

    CoverLast week, the U.S. Patent and Trademark Office released its FY 2018 Performance and Accountability Report.  In describing the USPTO's strategic and performance-planning framework, the 2018 Report notes that the Office issued its 2014-2018 Strategic Plan in 2014, and that the Plan "demonstrates the progress made to date by building on the tangible successes of recent years with a focus on achieving the USPTO's vision as a global IP leader by:

    • Establishing progress toward optimal pendency and quality levels for both patents and trademarks that will enable the USPTO to operate efficiently and effectively within the expectations of the IP community;
    • Administering effectively the provisions of the AIA;
    • Continuing to transform the USPTO with next-generation technology and services;
    • Maintaining a strong and diverse leadership team, agile management structure, and a diverse and engaged cadre of employees in achieving the agency's mission and vision;
    • Continuing to work with other government agencies, Congress, and the USPTO's global partners to establish IP systems that benefit innovation, create jobs, and lead to strong economies around the world; and
    • Recruiting and retaining the highest quality employees to accomplish the agency's important work."

    The 2018 Report specifies ten key performance outcome measures for which the Office has developed annual performance targets.  According to the Report, the Office exceeded its annual performance targets for nine of the ten performance measures.  Two of the ten measures fall within the Office's first strategic goal, which concerns optimizing patent quality and timeliness.  In particular, average first action pendency was 15.8 months (higher than the 15.4-month target, but lower than the 16.3-month average first action pendency of FY 2017), and average total pendency was 23.8 months (lower than the 25.0-month target and lower than the 24.2-month average total pendency of FY 2017).

    Table 3 of the Report provides data for the patent-related performance targets for FY 2014 to FY 2018 (click on any table to expand):

    Table 3_Strategic Goals
    The Report also notes that the number of applications filed decreased from 650,350 in FY 2017 to 643,349 in FY 2018, which constituted a 1.1% decrease in filings (see Table 1 below).  This followed a very slight decrease in application filings in FY 2017 and a 5.2% increase in application filings in FY 2016.

    Table 1_Patent Examining Activities
    The Report also indicates that while the Office accepted more than 600,000 patent applications for the sixth straight year and topped 500,000 applications for the ninth consecutive year (see Table 2 below), it was able to reduce the number of applications awaiting action from 569,088 in FY 2017 to 542,446 in FY 2018 (see Table 3 below).  The total number of pending applications also decreased from 1,082,661 in FY 2017 to 1,071,395 in FY 2018.  It was the Office's fourth consecutive reduction in number of applications awaiting action, but first drop in total number of pending applications since the Office's streak of consecutive reductions in total number of pending applications was snapped at five in FY 2017.

    Table 2_Applications Filed
    Table 3_Applications Pending
    After increasing from 304,568 utility patent issuances in FY 2016 to 315,366 in FY 2017, patent issuances once again dropped in FY 2018, falling to 306,909 (see Table 6 below).

    Table 6_Patents Issued
    As noted above, the results for first action and total pendency were mixed, with first action pendency coming in above the Office's target, and total pendency coming in below the Office's target (see Tables 4 and 5 below).  And as usual, the goals for the current fiscal year present even tougher challenges:  for first action pendency, the annual performance target drops from 15.4 months for FY 2018 (which the Office failed to meet) to 14.5 months for FY 2019, and for total pendency, the annual performance target drops from 25.0 months in FY 2018 (which the Office met) to 23.8 months in FY 2019.

    Table 4_Pendency
    Table 5_Pendency
    When comparing pendency statistics by Technology Center, Tech Center 2600 (communications) produced the best average first action pendency (11.0 months), with Tech Center 1600 (biotechnology and organic chemistry) following in second (12.5 months), and Tech Center 2100 (computer architecture, software, and information security) produced the worst average first action pendency (19.4 months) (see Table 4 below).  As for total average pendency, Tech Center 2600 also produced the best total average pendency (19.9 months), with Tech Center 2800 (semiconductor, electrical, optical systems, and components) following in second (21.6 months), and Tech Center 3700 (mechanical engineering, manufacturing, and products) and Tech Center 2100 (computer architecture, software, and information security) producing the worst total average pendency (28.4 months).

    Table 4_Technology Center

    For additional information regarding this and other related topics, please see:

    • "USPTO Releases Performance and Accountability Report for FY 2016," February 6, 2017
    • "USPTO Issues Performance and Accountability Report for FY 2015," March 3, 2016
    • "USPTO Issues Performance and Accountability Report for FY 2014," April 7, 2015
    • "USPTO Releases Performance and Accountability Report for FY 2013," January 9, 2014
    • "USPTO Releases Performance and Accountability Report for FY 2012," November 28, 2012
    • "USPTO Releases Performance and Accountability Report for FY 2011," November 30, 2011
    • "USPTO Releases 2010 Performance and Accountability Report," November 17, 2010
    • "USPTO Announces 'Highest Performance Levels in Agency's History' in 2008," November 18, 2008
    • "USPTO Announces 'Record Breaking' 2007 Performance," November 15, 2007
    • "Patent Office Announces Record-Breaking Year," December 27, 2006